Report summarizes adenoid cystic cancer study findings from Royal Marsden Hospital
2009 JUN 8 - (NewsRx.com) -- According to recent research published in the journal Clinical Oncology, "Adenoid cystic carcinoma (ACC) is a rare tumour that usually arises in the salivary glands. Initial management is surgery often combined with adjuvant radiotherapy." "Chemotherapy is reserved for treatment of symptomatic recurrence. We evaluated the combination of epirubicin, cisplatin and protracted venous infusion 5-fluorouracil (ECF) in the management of ACC. Patients referred for treatment of advanced, symptomatic ACC were considered. The drugs given were epirubicin 50 mg/m(2) 3-weekly, cisplatin 60 mg/m(2) 3-weekly and protracted venous infusion 5-fluorouracil 200 mg/m(2)/day. Eight patients (median age 46 years) received a median of five cycles of chemotherapy. All patients had had previous surgery, seven had had previous radiotherapy and one had had previous chemotherapy. One patient showed a partial response (duration 34 months) and five showed stable disease (median duration 13.6 months [6.8-15.9+ months]). Median survival was 27 months (3.5-62.3 months)," wrote P.J. Ross and colleagues, Royal Marsden Hospital. The researchers concluded: "The activity of ECF in ACC of the head and neck seems to be similar to the combination of cisplatin and 5-fluorouracil and single-agent epirubicin. Ross, P. J. et al. (2009)." Ross and colleagues published their study in Clinical Oncology (Epirubicin, Cisplatin and Protracted Venous Infusion 5-Fluorouracil Chemotherapy for Advanced Salivary Adenoid Cystic Carcinoma. Clinical Oncology, 2009;21(4):311-314). For additional information, contact C.M. Nutting, Royal Marsden Hospital, Dept. of Radiotherapy, Fulham Rd., London SW3 6JJ, UK. The publisher's contact information for the journal Clinical Oncology is: Elsevier Science London, 84 Theobalds Rd., London WC1X 8RR, England. Keywords: United Kingdom, London, Adenoid Cystic Cancer, Adenoid Cystic Carcinoma, Chemotherapy, Cisplatin, Clinical Oncology, Drug Therapy, Drugs, Epirubicin, Fluorouracil, Oncology, Pharmaceuticals, Surgery, Treatment, Royal Marsden Hospital. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
